mRNA-Based Therapeutics Summit 2026 Exhibitor List

Rajesh Krishnan is Vice President of Delivery Technology and Development at Providence Therapeutics, where he has been a key member of the leadership team since 2019. He leads research and CMC activities across lipid technologies, drug substances, and drug products, advancing innovative therapeutics from development through manufacturing. Rajesh holds a PhD in Chemistry and has more than 17 years of R&D experience across the pharmaceutical and biotechnology sectors.

Ph.D. of The University of Freiburg (Germany), Chijian has 10 years’ experience in pharmaceutical industry. Their focus is on circRNA based therapeutics development in the past 6 years.

Dr. Joshua McGee is the Chief Scientific Officer and Co-Founder of Keylicon Biosciences, where he leads development of next-generation vaccines and therapeutics across diverse targets. He earned his PhD in Biomedical Engineering from Boston University, where he developed modified self-amplifying RNA platforms, engineering lipid nanoparticle formulations, and designed novel saRNA vaccines and therapeutics.

Working at AstraZeneca for 25 years with experience in protein engineering and RNA Therapies. As part of a team successfully isolated, optimised and developed various antibodies to the clinic and market. Also, helped deliver mRNA based vaccines into the clinic. I’m currently working on multiple mRNA based therapeutics in different therapeutic areas for treatment of disease to improve patients lives.

Christine Tkaczyk is Director in the Microbial Antibody Technology group within Early Vaccines & immune Therapies at AstraZeneca, Gaithersburg, USA. At AstraZeneca, she spent 18 years developing monoclonal antibodies for serious bacterial infections. More recently, she expanded her research to develop mRNA platform for delivering diverse formats of monoclonal antibodies in vivo.

Ali Nahvi is the Chief Technology Officer at Nava Therapeutics where he is responsible for steering the company’s technology and innovation initiatives including chemistry, LNP discovery, targeted delivery, process development and manufacturing. Prior to joining Nava, Ali was the Head of Platform at Flagship Pioneering’s Mirai Bio, where he helped to start the company from inception, implement the company’s scientific strategy and led it through to its next stage of growth. Previously, Ali served as Head of New Therapeutic Modalities at Spark Therapeutics and was responsible for driving research-related activities to expand the applicability of AAV and non-viral gene therapy platforms. Ali holds a Ph.D. from Yale University and was a Life Sciences Research Foundation postdoctoral fellow at Johns Hopkins School of Medicine characterizing the mechanisms of RNA mediated gene regulation.

Nikola A. Ivica, PhD is a co-founder and Chief Scientific Officer of InnDura Therapeutics, where he is advancing innovative cell and gene therapy platforms for a range of therapeutic indications. He trained at MIT as a PhD student and postdoctoral fellow with Professor Jianzhu Chen, PhD and completed his undergraduate studies at Harvard University.